Candel Therapeutics, Inc. (CADL) Research

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

Market snapshot

Symbol
CADL
Price
$8.31
Day change
+4.01%
Market cap
$456.2M
P/E ratio
-9.52x
52-week range
4.35-9.57
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$15.00

Recent news

  • Fed holds rates, but rare split exposes deepening divide

    The US Federal Reserve left interest rates unchanged on Wednesday, in line with market expectations, but policymakers showed an unusual split over the path...

  • Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch

    Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer patients, has signed a commercialization agreement with EVERSANA, a global commercialization services provider, to gear up for the potential US launch of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk, localized prostate cancer. Under the deal, EVERSANA will deliver an integrated range of services covering data and analytics, medical affairs, market access, and field operations.

  • Regeneron shares slide despite Q1 beat

    Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares fell more than 5.5% on Wednesday morning even as the drugmaker reported better-than-expected...

Peer companies

  • Aldeyra Therapeutics, Inc. (ALDX)
  • Cabaletta Bio, Inc. (CABA)
  • Capricor Therapeutics, Inc. (CAPR)
  • Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
  • Editas Medicine, Inc. (EDIT)
  • Genelux Corporation (GNLX)
  • Immutep Limited (IMMP)
  • Kyverna Therapeutics, Inc. (KYTX)

Recent insider activity

  • Manning Paul B — A-Award (4618 shares) on 2026-03-31
  • PAPA JOSEPH C — A-Award (2795 shares) on 2026-03-31
  • Loggia Nicoletta — A-Award (779 shares) on 2026-03-31
  • Manning Paul B — P-Purchase (550458 shares) on 2026-02-23
  • Tyagarajan Seshu — A-Award (154000 shares) on 2026-01-26

Open Candel Therapeutics, Inc. (CADL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.